Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

OFLOXACIN

All products: Limited Use (codes 170)

Other products in the same Health Canada class (S01AE) — coverage varies; not interchangeable

  • Ciprofloxacin (Ciloxan): not a benefit

Ocuflox · DIN 02143291 · 0.3% · Oph Sol

Limited Use — Reason for Use code 170 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 170 required
Write on scriptLU code 170 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 170
Reason for Use code 170 For the treatment of conjunctivitis caused by susceptible strain(s) of Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae and Hemophilus influenzae which is/are resistant or unresponsive to listed alternative agents. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Ocuflox · DIN 02143291 Manufacturer: Allergan Inc.; listing date 1996-12-19 Health Canada: Marketed since 2024-05-27 · brand OCUFLOX · ATC S01AE01 OFLOXACIN · form Solution · route Ophthalmic · ingredients OFLOXACIN 0.3 %/W/V · company Abbvie corporation · schedule Prescription
Check this DIN again · Health Canada product record

Ocuflox: Formulary list price $2.8720/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.8720 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18491 · Verify on the e-Formulary ↗ (DIN 02143291)

Source record
DIN 02143291: Ocuflox Raw flags: sec12=Y, sec3=Y Item: 520412008; group id 587; item number 1544; lccId 00080; manufacturer id ALL Source form: Oph Sol; strength: 0.3% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.8720; ministry $2.8720 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02143291 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18491
Shortage status: active shortage (reported 2025-08-12, estimated to end 2026-10-09, last updated 2026-09-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02143291
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (52:04:12 Other Anti-Infectives) and how they are covered

Matched class: 52:04:12 Other Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 52:04:12 Other Anti-Infectives

CIPROFLOXACIN

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.3% · Oph Sol-5mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:04:12
Full class listing Related classes: 52:04:04 Antibiotics, 52:08:92 Anti-Inflammatory Agents, Miscellaneous Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS OCUFLOX® (ofloxacin) is indicated for the treatment of conjunctivitis when caused by susceptible strains of the following bacteria: Gram Positive Bacteria • Staphylococcus aureus • Staphylococcus epidermidis • Streptococcus pneumoniae Gram Negative Bacteria • Haemophilus influenza To reduce the development of drug-resistant bacteria and maintain the effectiveness of OCUFLOX and other antibacterial drugs, OCUFLOX should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. 1.1 Pediatrics Pediatrics (< 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of OCUFLOX in pediatric patients has not been established. Therefore, Health Canada has not authorized an indication for pediatric use. See 7.1.3 Pediatrics. 1.2 Geriatrics Geriatrics (> 65 years of age): No comparative data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use. https://pdf.hres.ca/dpd_pm/00067076.PDF PM date: NOV 25, 1994 Source product: OCUFLOX; DIN 02143291; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Ocuflox · DIN 02143291 Shortage status: active shortage (reported 2025-08-12, estimated to end 2026-10-09, last updated 2026-09-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02143291

Check this DIN again